Silexion Therapeutics Ltd.
SLXNW · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -7,130.75% | -10,581.22% | -474.17% | -4,668.07% |
| EV / EBITDA | 2.68 | -0.10 | 1.25 | -0.57 |
| Quality | ||||
| ROIC | -36.57% | -59.82% | -27.19% | -378.49% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.87 | 1.00 | 1.41 | 1.67 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -13.36% | -1.99% | 15.96% | -9.63% |
| Safety | ||||
| Net Debt / EBITDA | 2.69 | -0.09 | 1.55 | -0.56 |
| Interest Coverage | 0.00 | 0.00 | -183.33 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -20,760.00 | -16,245.00 | 0.00 |